DiveRadGel Co., Ltd. (Headquarters: Chuo‑ku, Tokyo; CEO: Takashi Nakai; hereinafter
“DiveRadGel”) today announced the initiation of a collaborative research program with
Professor Takayuki Kanaseki and colleagues at Division of Cancer Immunology, Graduate
School of Medical and Dental Sciences, Niigata University, to develop an off‑the‑shelf
cancer vaccine. The program combines shared neoantigens derived from long non‑coding
RNAs (lncRNAs) with DiveRadGel’s conventional type 1 dendritic cell (cDC1) targeted drug
delivery system (DDS).